Investor's Eye
[July 07, 2008] | | |
| Summary of Contents SHAREKHAN SPECIAL Q1FY2009 FMCG earnings preview Expect margins to be under pressure
We expect the overall revenues of Sharekhan's FMCG universe to increase by 13.2% year on year (yoy). The revenue growth was on the back of a steady volume growth and hefty price hikes during the quarter and the last twelve months. The volumes and prices were increased primarily to combat the steep increase in the raw material costs. During the quarter, we expect the margins of all the FMCG companies to be under pressure in spite of the price hikes affected by the companies, as the companies would see an increase in their input costs. Thus, we expect the operating profit for Sharekhan FMCG universe to grow only by 6.2% and the adjusted net profit for the quarter to grow by a meagre 6.9%.
STOCK UPDATE Cadila Healthcare
Cluster: Emerging Star
Recommendation: Buy
Price target: Rs372
Current market price: Rs314 Price target revised to Rs372 Key points -
Cadila Healthcare (Cadila) has decided to hive-off its consumer product business and merge the same with its listed subsidiary, Carnation Nutra Analogue (Carnation). In consideration, Carnation will allot to shareholders of Cadila four fully paid up equity shares of Rs10 each for 15 equity shares of Rs5 each held in Cadila. Consequently, Cadila's stake in Carnation would increase from 61.56% currently to 70.2% post the restructuring. -
Cadila would also amalgamate Zydus Hospital and Medical Research Private Ltd (ZHMRPL) with itself by cancelling the existing nine crore shares held by ZHMRPL in Cadila and issuing 10.08 crore fresh equity shares to ZHMRPL. The move would result in equity dilution of 8.7% in Cadila and add no value for the minority shareholders. -
The restructuring is intended to consolidate the group's consumer product business under one entity and aims to unlock value in its consumer product business. -
To factor in the equity dilution and de-merger of the consumer product business, we have revised downwards our consolidated earnings estimates for FY2009 and FY2010 by 8.3% and 8.4% respectively. However, in consideration for the consumer product business, Cadila shareholders would get additional shares of Carnation (in the ratio of four shares of Carnation for every 15 shares of Cadila). We have valued Carnation at Rs87 per share (10x FY2010E earnings). -
Thus, we believe that the restructuring process is largely neutral from the point of view of minority shareholders. We maintain our Buy call with a revised price target of Rs372. | |
Read More...
Summary only...
Disclaimer
This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.
The information contained herein is from publicly available data or other sources believed to be reliable. While I would endeavour to update the information herein on reasonable basis, I am under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent me from doing so. I do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. I do not undertake to advise you as to any change of my views. I may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject me to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. I may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. I may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall I or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.
